New-Generation ACURATE Neo2

Transcatheter aortic valve replacement (TAVR) is a therapeutical option for patients with symptomatic severe aortic stenosis. Current guidelines recommend TAVR in patients ≥75 years with intermediate risk. One of the most frequent complications of this procedure is moderate or greater aortic regurgitation (AR) after implantation. Consequently, new valves have been developed to try and reduce the incidence of this complication.

Nueva generación de ACURATE Neo2

The target of this observational, retrospective, multicenter study was evaluating the safety and efficacy of the ACURATE Neo2 valve in the real world, comparing short-term clinical and hemodynamic outcomes in patients treated with first-generation ACURATE Neo.

The primary endpoint (PEP) was moderate of greater AR as measured by echocardiogram. The secondary endpoint (SEP) was technical success of the procedure, and efficacy and safety of the device at 90 days.

This study included 900 patients; 220 had the ACURATE Neo2 valve implanted, and 680 received a first-generation ACURATE Neo device. Mean patient age was 83 years old, and most subjects were female. The Society of Thoracic Surgeons (STS) score was 3.6, and about 9% of patients had a prior permanent pacemaker implanted.

Patients in the ACURATE Neo2 arm experienced grade 1 atrioventricular block and complete right bundle branch block more frequently than patients in the other group. In terms of the procedure, access was transfemoral in all cases; in the ACURATE Neo2 group, pre-dilation was significantly more used, while post-dilation was more frequent in the other arm.

Read also: Bad prognosis for post-MitraClip mitral valve stenosis: how do we proceed?

The post-procedure success rate was similar in both arms, with no differences in in-hospital major adverse events. There was a decrease in the frequency of moderate or greater AR with the use of ACURATE Neo2 compared with first-generation ACURATE Neo (11.2% vs. 3.5%; p < 0.001).

Conclusion

Compared with the first-generation device, the new-generation ACURATE Neo2 was associated with a significantly lower frequency of moderate or severe paravalvular AR. Despite the encouraging results of this new-generation ACCURATE device, further randomized and long-term studies are needed to support these results.

Dr. Andrés Rodríguez
Member of the Editorial Board of SOLACI.org.

Original Title: Transcatheter Aortic Valve Replacement With Self-Expanding ACCURATE neo2 Postprocedural Hemodynamic and Short-Term Clinical Outcomes.

Reference: Andrea Buono, MD et al J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...